Evonik stock falls as analysts and peers turn cautious

Evonik stock (DE000EVNK013) fell 4.84 percent on September 19, 2026, after a weak peer-group session added pressure to the shares. The stock was listed at EUR 14.85 in the latest market snapshot from finanznachrichten.de, and the move leaves investors weighing price action against the companys most recent reported numbers.

Half-year figures matter

Evonik reported revenue of EUR 7.25 billion for the first half of 2026, while adjusted EBITDA reached EUR 703 million and the adjusted EBITDA margin stood at 9.7 percent, according to the companys half-year report dated August 1, 2026. Revenue was down from EUR 7.66 billion in the first half of 2025, a decline of 5.4 percent.

That comparison is the key point for investors. The margin held below 10 percent in the period ended June 30, 2026, so the stock is being judged less on a single day of trading than on whether earnings can stabilize.

Analyst tone stays cautious

MarketScreener showed Evonik among the names in its analyst overview on September 18, 2026, alongside Commerzbank and other houses, which underlines that the stock remains on institutional watchlists. The same kind of coverage matters because it often turns the focus to pricing power, margins and the next reporting date.

A second reference point is the broader market backdrop: the peer-group note on Börse Social on September 19, 2026, listed Evonik at minus 4.84 percent in a German small-cap comparison table. For a chemical group with a 9.7 percent adjusted EBITDA margin in the first half of 2026, that kind of session keeps valuation sensitivity high.

Price and market view

The latest available market line puts Evonik stock at EUR 14.85 on its German listing, with the session down 4.84 percent as of September 19, 2026. For the moment, that leaves the shares trading against a backdrop of EUR 7.25 billion revenue, EUR 703 million adjusted EBITDA and a 9.7 percent margin in the first half of 2026.

More news and analyses on Evonik stock